GleamWall
中文EN

COYA Coya Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1835022 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.6%
TTM net income YoY-63.7%
TTM EPS YoY-25.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-675.3%
Net margin-643.5%
FCF margin—
EBITDA margin-675.0%

Returns

ROE-99.2%
ROA-84.6%
ROIC (approx.)—
Asset turnover0.13x

Leverage & solvency

Liabilities / assets14.6%
Debt / equity0.00x
Current ratio7.24x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.72x
Accruals ratio-23.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$7.95M$3.55M
R&D expense$16.73M$11.87M
SG&A expense$11.45M$8.89M
Operating income-$22.56M-$17.25M
Pretax income-$21.22M-$15.60M
Income tax$3,089-$720,287
Net income-$21.23M-$14.88M
EBITDA-$22.53M-$17.22M
EPS (basic)-1.27-0.98
EPS (diluted)-1.27-0.98
Weighted avg. shares (diluted)16.73M15.24M
Balance sheet
Cash & equivalents$46.82M$38.34M
Current assets$49.94M$44.31M
PP&E, net$11,227$38,588
Total assets$49.95M$44.35M
Current liabilities$5.87M$3.82M
Total liabilities$6.92M$4.77M
Shareholders' equity$43.03M$39.58M
Shares outstanding20.93M16.71M
Cash flow statement
Operating cash flow-$10.74M-$10.29M
Investing cash flow-$1.16M-$25,000
Financing cash flow$20.39M$16.03M
Depreciation & amortization$27,361$27,361
Stock-based compensation$4.29M$2.66M

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.